The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation

Zhu, 2020, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, 382, 727, 10.1056/NEJMoa2001017 Islam, 2020, Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries, BMJ, 370 Jit, 2020, Estimating number of cases and spread of coronavirus disease (COVID-19) using critical care admissions, United Kingdom, February to March 2020, Euro Surveill, 25, 10.2807/1560-7917.ES.2020.25.18.2000632 Orr, 2015, Reconciling cost-effectiveness with the rule of rescue: the institutional division of moral labour, Theory Decis, 78, 525, 10.1007/s11238-014-9434-3 Mahase, 2020, Covid-19: What do we know about the late stage vaccine candidates?, BMJ, 371 Davies, 2020, Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study, Lancet Public Health, 5, e375, 10.1016/S2468-2667(20)30133-X Poland, 2020, SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates, Lancet, 396, 1595, 10.1016/S0140-6736(20)32137-1 Huang, 2020, A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity, Nat Commun, 11, 10.1038/s41467-020-18450-4 Davies, 2021, Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England, Science, 10.1126/science.abg3055 Hellewell, 2020, Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts, Lancet Glob Health, 8, e488, 10.1016/S2214-109X(20)30074-7 Polack, 2020, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, N Engl J Med, 383, 2603, 10.1056/NEJMoa2034577 Voysey, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet, 397, 99, 10.1016/S0140-6736(20)32661-1 Krause, 2020, COVID-19 vaccine trials should seek worthwhile efficacy, Lancet, 396, 741, 10.1016/S0140-6736(20)31821-3 Kissler, 2020, Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period, Science, 368, 860, 10.1126/science.abb5793 2021, COVID-19: the green book, chapter 14a 2013 2013, Report from the Working Group on Uncertainty in Vaccine Evaluation and Procurement, 34 Claxton, 1999, The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies, J Health Econ, 18, 341, 10.1016/S0167-6296(98)00039-3 Glover, 2010 Pronker, 2013, Risk in vaccine research and development quantified, PLoS One, 8, 10.1371/journal.pone.0057755 Schonberger, 2020, Cost benefit analysis of limited reopening relative to a herd immunity strategy or shelter in place for SARS-CoV-2 in the United States, medRxiv Padula, 2020, Economic value of treatment and vaccine to address the COVID-19 pandemic: a US cost-effectiveness and budget impact analysis, SSRN, 10.2139/ssrn.3586694 Saad-Roy, 2020, Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years, Science, 370, 811, 10.1126/science.abd7343 Sandmann, 2018, Estimating the opportunity costs of bed-days, Health Econ, 27, 592, 10.1002/hec.3613 O'Brien, 2002, Is there a kink in consumers' threshold value for cost-effectiveness in health care?, Health Econ, 11, 175, 10.1002/hec.655 Chilton, 2020, Beyond COVID-19: How the ‘dismal science’ can prepare us for the future, Health Econ, 29, 851, 10.1002/hec.4114 Wang, 2020, Modelling Covid-19 under uncertainty: what can we expect?, Eur J Health Econ, 21, 665, 10.1007/s10198-020-01202-y Carfì, 2020, Persistent symptoms in patients after acute COVID-19, JAMA, 324, 603, 10.1001/jama.2020.12603 Sud, 2020, Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study, Lancet Oncol, 21, 1035, 10.1016/S1470-2045(20)30392-2 Abbas, 2020, Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit–risk analysis of health benefits versus excess risk of SARS-CoV-2 infection, Lancet Glob Health, 8, e1264, 10.1016/S2214-109X(20)30308-9 Saxena, 2020, Routine vaccination during covid-19 pandemic response, BMJ, 369 McDonald, 2020, Early impact of the coronavirus disease (COVID-19) pandemic and physical distancing measures on routine childhood vaccinations in England, January to April 2020, Euro Surveill, 25, 10.2807/1560-7917.ES.2020.25.19.2000848 Lo, 2005, Respiratory infections during SARS outbreak, Hong Kong, 2003, Emerg Infect Dis, 11, 1738, 10.3201/eid1111.050729